C3i at ISCT 2025: An International Showcase for Our CDMO Capabilities

A strategic gathering at the crossroads of innovation, regulation, and global partnerships

From May 7 to 10, 2025, C3i participated in the International Society for Cell & Gene Therapy (ISCT), a major global conference held this year in New Orleans. Bringing together leading experts and organizations in the field, ISCT serves as a key hub for advancing cell and gene therapies. C3i proudly showcased its integrated CDMO offering with a strong message:

We are the first Canadian CDMO authorized by Health Canada for commercial manufacturing of cell therapies, and now also approved by the EMA to manufacture cell therapy products for the European market.

With this dual regulatory recognition, C3i offers its partners local expertise of the Cold Chain Logistic, combining quality, compliance, and accelerated time-to-market. Our representatives, Jamie Sharp, Ph.D., and Cynthia Thérien, engaged with numerous industry leaders at booth #545, emphasizing the importance of building strong bridges between regulation, production, and innovation.

ISCT 2025 represents a significant milestone for C3i’s global reach and reinforces our commitment to cutting-edge manufacturing in service of patients worldwide.